Project Grant R41AI195068
Award Date 9/11/25
Completion Date 8/31/27
Dollars Obligated $300K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $258,750 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to HBVTech, LLC, a small disadvantaged business located in Germantown, Maryland. The grant funding supports the development of HBVZ10, a new gene therapy candidate aimed at producing sustained high levels of anti-hepatitis B surface antigen antibodies to block hepatitis B virus (HBV) reinfection and potentially...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $320,863 to Jericho Sciences, LLC to support the translational development of a small molecule therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The project aims to validate the proposed drug target, the hepatitis B X regulatory protein (HBx), which plays a critical role in HBV covalently...
- This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $5,504,270 Cooperative Agreement to The Johns Hopkins University on September 26, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The award will establish a multinational cohort of people with HIV and chronic hepatitis B (PWHHB) to apply novel technologies and advance a hepatitis B virus (HBV) functional cure. The project aims to characterize mechanisms of intrahepatic HBV...
- This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
- This $814,790 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to uncover the immune mechanisms underlying hepatitis B virus (HBV) surface antigen clearance, which can lead to a clinical cure for chronic HBV infection. The principal investigators at the University of California, San Francisco (UCSF) will leverage mouse models and clinical samples from HBV patients to conduct a...
- The U.S. Defense Health Agency awarded a $4,728,039 Project Grant to HBVtech, L.L.C., a minority-owned small disadvantaged business located in Germantown, Maryland, under the Military Medical Research and Development program (CFDA 12.420). The grant supports the development of a new hepatitis B virus (HBV) cure treatment regimen aimed at the durable elimination of HBV covalently closed circular DNA (cccDNA) in chronic HBV infections. The research activities focus on exploring unconventional...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $806,208 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Weill Medical College of Cornell University. The project, titled "Spatial Omics to Understanding HBV Control in People with HIV Coinfection," will leverage cutting-edge spatial proteomic and transcriptomic technologies to analyze the impact of HIV-related immune suppression and restoration on the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $972,583 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Research Institute at Nationwide Children's Hospital in Ohio. The grant, titled "Defining Successful Intrahepatic CD4+ T Cell Responses Against the Hepatitis C Virus," aims to study protective CD4+ T cell responses in order to develop an effective vaccine against chronic Hepatitis C virus (HCV) infection....